AUTHOR AND EDITOR INFORMATION

Section 1 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

INTRODUCTION

Section 2 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Background

Tumor lysis syndrome (TLS) refers to the constellation of metabolic disturbances that may be seen after initiation of cancer treatment. Tumor lysis syndrome usually occurs in patients with bulky, rapidly proliferating, and treatment-responsive tumors. Tumor lysis syndrome is typically associated with acute leukemias and high-grade non-Hodgkin lymphomas, such as Burkitt lymphoma. TLS also has been reported with other hematologic malignancies and solid tumors.

A potentially lethal complication of anticancer treatment, tumor lysis syndrome occurs when large numbers of neoplastic cells are killed rapidly, leading to release of intracellular ions and metabolic byproducts into the systemic circulation. Clinically, the syndrome is characterized by rapid development of hyperuricemia, hyperkalemia, hyperphosphatemia, hypocalcemia, and acute renal failure (ARF). The main principles of tumor lysis syndrome management are (1) identification of high-risk patients with initiation of preventive therapy and (2) early recognition of metabolic and renal complications with prompt supportive care, including hemodialysis.

Pathophysiology

Rapid tumor cell turnover results in release of intracellular contents into the circulation. This release can inundate renal elimination and cellular buffering mechanisms, which lead to numerous metabolic derangements. Clinically significant tumor lysis syndrome can occur spontaneously, but it is most often seen 48-72 hours after initiation of cancer treatment. Hyperkalemia is often the earliest laboratory manifestation. Hyperkalemia and hyperphosphatemia result directly from rapid cell lysis. Nucleic acid purines, which are also released by cell breakdown, are ultimately metabolized to uric acid by hepatic xanthine oxidase. This conversion leads to hyperuricemia. Hypocalcemia is a consequence of acute hyperphosphatemia with subsequent precipitation of calcium phosphate in soft tissues. In acute renal failure, decreased calcitriol levels also cause hypocalcemia.

Uric acid is the terminal catabolic product of purine metabolism in humans; it is a weak acid with pKa of approximately 5.4, is soluble in plasma, and is freely filtered at the renal glomeruli. However, uric acid is less soluble in renal tubular and collecting duct fluid due to normally acidic media, thus increasing the possibility of uric acid crystal formation in case of hyperuricemia.

The kidney is the primary organ involved in clearance of uric acid, potassium, and phosphate. Preexisting volume depletion or renal dysfunction predisposes patients to worsening metabolic derangements and acute renal failure. Acute renal failure is often oliguric and can be multifactorial in etiology; uric acid nephropathy is the major cause of acute renal failure. Its development is due to mechanical obstruction by uric acid crystals in the renal tubules. With a pKA of 5.6, uric acid precipitation is enhanced by high acidity and high concentration in the renal tubular fluid, becoming less soluble as renal tubule pH decreases. Renal medullary hemoconcentration and decreased tubular flow rate also contribute to crystallization.

Another cause of acute renal failure is acute nephrocalcinosis from calcium phosphate crystal precipitation, which may occur in other tissues. This occurs in the setting of hyperphosphatemia and is exacerbated by overzealous iatrogenic alkalinization, because calcium phosphate, unlike uric acid, becomes less soluble at an alkaline pH. Precipitation of xanthine, which is even less soluble in urine than uric acid, or other purine metabolites whose urinary excretion is increased by use of allopurinol, are other causes of acute renal failure.

Frequency

International

Incidence is unknown. Prevalence varies among different malignancies; bulky, aggressive, and treatment-sensitive tumors are associated with higher frequencies of tumor lysis syndrome. In studies of frequency in patients with intermediate-grade or high-grade non-Hodgkin lymphomas, laboratory evidence of tumor lysis syndrome (42%) occurred much more frequently than the symptomatic clinical syndrome (6%). In children with acute leukemia receiving induction chemotherapy, silent laboratory evidence of tumor lysis syndrome occurred in 70% of cases, but clinically significant TLS occurred in only 3%. As advances are made in cancer treatment and as high-dose regimens become more commonplace, tumor lysis syndrome incidence may increase and the syndrome emerge in a broader spectrum of malignancies.

Mortality/Morbidity

• Acute renal failure: Renal tubule precipitation of uric acid, calcium phosphate, or hypoxanthine causes acute renal failure. This is often oliguric ( <400 mL/d) in nature, leading to volume overload and complications of hypertension and pulmonary edema. High blood urea nitrogen (BUN) levels due to increased protein catabolism and renal impairment can be severe enough to result in pericarditis, platelet dysfunction, and defective cellular immunity. Renal dysfunction can be severe enough to require dialysis, but with prompt supportive measures, it is usually reversible.
• Cardiac arrhythmia: Hyperkalemia can lead to ECG changes and life-threatening cardiac arrhythmia, including asystole. Severe potassium elevation can cause ECG alterations such as peaked T waves, flattened P waves, prolonged PR interval, widened QRS complexes, deep S wave, and sine waves. Hypocalcemia can lead to QT interval lengthening, which predisposes patients to ventricular arrhythmia.
• Metabolic acidosis: Acute renal failure and liberation of large amounts of endogenous intracellular acids from cellular catabolism result in acidemia. This acidemia causes a decrease in serum bicarbonate concentration and a high anion gap acidosis. Acidemic states can worsen the many electrolyte imbalances already present in TLS; intracellular uptake of potassium is hindered, uric acid solubility is decreased, and extracellular shift of phosphate is promoted. Calcium phosphate solubility, however, improves in acidic conditions. The myriad of metabolic disorders must be assessed and treated rapidly. Proper fluid management, alkalinization of the urine, correction of acidosis, and attention to infections are the mainstays of therapy.

Race

No racial predilection exists.

Sex

No sex predilection exists.

Age

Although tumor lysis syndrome occurs in all age groups, advanced age leading to impaired renal function may predispose patients to clinically significant tumor lysis syndrome owing to decreased ability to dispose of tumor lysis byproducts.

CLINICAL

Section 3 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

History

A constellation of clinical symptoms, such as nausea, vomiting, lethargy, edema, fluid overload, congestive heart failure, cardiac dysrhythmias, seizures, muscle cramps, tetany, syncope, and sudden death may develop prior to initiation of chemotherapy or more commonly within 72 hours after administration of cytotoxic therapy.

Physical

• Symptoms reflect the severity of underlying metabolic abnormalities.
• Hyperkalemia can cause paresthesia and weakness. Severe hypocalcemia can also lead to paresthesia and tetany with positive Chvostek and Trousseau signs, anxiety, carpal and pedal spasms, and bronchospasm.
• Uremia can manifest as fatigue, weakness, malaise, nausea, vomiting, anorexia, metallic taste, hiccups, neuromuscular irritability, difficulty concentrating, pruritus, restless legs, and ecchymoses. As uremia progresses, paresthesia and evidence of pericarditis may develop, as well as signs of drug toxicity for administered medications eliminated by the kidney. Features of volume overload, such as dyspnea, pulmonary rales, edema, and hypertension, may develop.
• Rapidly increasing uric acid levels may lead to arthralgia and renal colic.

Causes

• Tumor lysis syndrome occurs most often in patients with acute leukemia with high WBC counts and in those with high-grade lymphomas in response to aggressive treatment. Tumor lysis syndrome also may occur in other hematologic malignancies and in a variety of solid tumors. It has occasionally occurred spontaneously, prior to any form of therapy.
• Those at highest risk have bulky, rapidly proliferating tumors that are sensitive to treatment. An elevated pretreatment lactate dehydrogenase (LDH) level, which correlates with high tumor volume, is a strong prognostic indicator for developing clinically significant complications of therapy. Presence of renal insufficiency prior to therapy also is correlated with an increased likelihood of tumor lysis syndrome.
• There are reports of tumor lysis syndrome associated with the administration of radiation therapy, corticosteroids, hormonal agents, biologic response modifiers, monoclonal antibodies.
  Agents reported to cause tumor lysis syndrome include paclitaxel, fludarabine, etoposide, thalidomide, bortezomib, zoledronic acid, and hydroxyurea.
• Tumor lysis syndrome is not limited to systemic administration of agents; it can occur with intrathecal administration of chemotherapy and with chemo-embolization.
• Rare clinical situations in which tumor lysis syndrome has been observed include pregnancy and fever. Patients under general anesthesia have also experienced tumor lysis syndrome.

DIFFERENTIALS

Section 4 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Other Problems to be Considered

Patients with cancer are at increased risk of renal failure from etiologies other than tumor lysis syndrome. Prerenal causes include volume depletion from anorexia, vomiting, diarrhea, and bleeding. Pelvic or retroperitoneal masses can lead to kidney failure from postrenal urinary tract obstruction. Renal parenchymal diseases include tumor infiltration, myeloma kidney, drug nephrotoxicity from chemotherapeutic agents or antibiotics, radiocontrast nephropathy, vasculitis, and cryoglobulinemic glomerulonephritis. The combination of volume depletion, hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia strongly support the diagnosis of tumor lysis syndrome over other causes.

WORKUP

Section 5 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Lab Studies

• Blood chemistry
• • Most patients have laboratory derangements in potassium, phosphate, calcium, and uric acid, and abnormal renal functions, occurring 1-3 days following chemotherapy initiation.
  • Hyperkalemia is often the first life-threatening abnormality.
  • High-risk patients should have laboratory monitoring (BUN, creatinine, phosphate, uric acid, LDH, and calcium) prior to therapy and for 48-72 hours after treatment induction. Follow measurements at least twice daily or more often if evidence of tumor lysis syndrome develops.
• Urine pH
• • If hyperuricemia develops, urine alkalinization prevents renal precipitation of uric acid.
  • If alkaline diuresis is employed, regular determinations of urine pH should guide the extent of therapy.

Other Tests

• Because increased urine flow rates help to inhibit crystal deposition in renal tubules, close monitoring of urine output is necessary to assess adequacy of hydration. Monitoring urine output for signs of oliguric renal failure is also necessary.
• Frequent cardiac assessment (ECG or continuous cardiac monitoring) is necessary to monitor electrocardiographic changes, which may herald a lethal arrhythmia caused by potassium and calcium disturbances.

Histologic Findings

Pathologic studies demonstrate deposits of uric acid within the distal renal tubule lumina, causing intrarenal hydronephrosis. Uric acid crystals can also be seen within tubular epithelial cells and the medullary microcirculation. Uric acid precipitates may also occur in the renal pelvis and ureters, leading to hydronephrosis and acute renal failure from extrarenal sources.

TREATMENT

Section 6 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Medical Care

• Overview
• • The identification of patients at risk for the development of tumor lysis syndrome is the most important aspect of management as prophylactic measures may be initiated before the initiation of therapy.
  • • Most of the complications can be readily managed when they are recognized early; however, delay in recognition and initiation of treatment of tumor lysis syndrome can be life-threatening.
    • • Tumor lysis syndrome management requires initiation of preventive measures in high-risk patients prior to cancer treatment as well as prompt initiation of supportive care for patients who develop acute tumor lysis syndrome during treatment.
      • Patients with evidence of pretreatment acute tumor lysis syndrome should be started immediately on tumor lysis syndrome treatment, withholding cancer therapy if possible until all parameters are corrected. Identify high-risk patients before treatment by assessing the extent of tumor burden, histopathologic findings, and renal function.
      • Conservative management and prevention of tumor lysis syndrome are similar and are discussed together.
• Hospital setting
• • Cancer patients with acute manifestations of tumor lysis syndrome or those at high risk should be treated by personnel who are experienced with tumor lysis syndrome complications and treatment. An oncology unit or ICU with readily available continuous cardiac monitoring and hemodialysis capabilities is preferable.
  • If basic supportive care measures are ineffective in controlling electrolyte disturbances or renal function, nephrology and critical care consultants should be accessible to assist in further management.
  • Laboratory turnover time must be rapid so that metabolic derangements can be addressed before life-threatening problems arise.
• Surveillance
• • Severe manifestations of tumor lysis syndrome can be prevented only through meticulous laboratory monitoring and careful clinical observation. Necessary cardiac studies include baseline ECG with follow-up studies or continuous cardiac monitoring during treatment. Appropriate renal surveillance and fluid status determinations require baseline and daily weights, regular vital sign checks, and frequent measurements of both fluid intake and urine output.
  • Patients at high risk and those with evidence of tumor lysis syndrome should have at least thrice-daily laboratory monitoring of BUN, creatinine, uric acid, potassium, calcium, phosphate, and LDH. Monitoring should continue for the first 48-72 hours after chemotherapy initiation.
• Control of hyperuricemia
• • Allopurinol is a xanthine oxidase inhibitor and is given to reduce the conversion of nucleic acid byproducts to uric acid in order to prevent urate nephropathy and subsequent oliguric renal failure. It usually is given orally as 600 mg/d for prophylaxis and 600-900 mg/d (up to a maximum of 500 mg/m²/d) for treatment of tumor lysis syndrome. Patients unable to take oral medications can be given intravenous allopurinol. Adverse effects include mild to severe rash, xanthine stone-induced urolithiasis, acute interstitial nephritis, pneumopathy, fever, and eosinophilia. Dose reduction is necessary in renal insufficiency; dose reduction is also necessary if given concomitantly with mercaptopurine, 6-thioguanine, or azathioprine, since allopurinol interferes with the metabolism of these agents.
  • Rasburicase (recombinant urate oxidase) is a newer therapy that can be used when the uric acid levels cannot be lowered sufficiently by standard approaches. Rasburicase is useful in cases of hyperuricemia. Humans don't express urate oxidase; urate oxidase catalyses the conversion of poorly soluble uric acid to soluble allantoin. By converting uric acid to water-soluble metabolites, it effectively decreases plasma and urinary uric acid levels. Unlike allopurinol, uricase does not increase excretion of xanthine and other purine metabolites; therefore, it does not increase tubule crystallization of these compounds. It is administered by intramuscular injection or intravenous infusion at dosages ranging from 50-100 U/kg/d. It is contraindicated in glucose-6-phosphate dehydrogenase (G-6-PD) deficiency and pregnancy.

    In G-6-PD deficiency, as rasburicase breaks down uric acid and accelerates catabolism of its precursors xanthine and hypoxanthine, excess hydrogen peroxide accumulates from G-6-PD deficiency, placing patients at risk for both hemolytic anemia and methemoglobinemias. Some authorities recommend screening for G-6-PD deficiency prior to administration of the drug. Studies are underway to establish safety and efficacy in those populations at highest risk for developing tumor lysis syndrome. It is approved by the U.S. Food and Drug Administration (FDA) for the prevention and treatment of hyperuricemia and tumor lysis syndrome in pediatric patients with leukemia, lymphoma, or solid organ malignancy receiving chemotherapy. It is also indicated in treatment of adults in countries like Australia, Canada, and in parts of Europe. Since humans do not express urate oxidase, rasburicase can potentially elicit an immune response.

• Hydration
• • Volume depletion is a major risk factor for tumor lysis syndrome and must be corrected vigorously. Aggressive intravenous hydration not only helps correct electrolyte disturbances by diluting extracellular fluid, but it also increases intravascular volume. Increased volume enhances renal blood flow, glomerular filtration rate, and urine volume to decrease the concentration of solutes in the distal nephron and medullary microcirculation.
  • Ideally, intravenous hydration in high-risk patients should begin 24-48 hours prior to initiation of cancer therapy and continue for 48-72 hours after completion of chemotherapy.
  • Continuous infusion rates as high as 4-5 L/d (or 3 L/m²/d) yielding urine volumes of at least 3 L/d should be given unless the patient's cardiovascular status indicates impending volume overload.
• Urinary alkalinization
• • Use of isotonic sodium bicarbonate solutions intravenously to promote alkaline diuresis has the potential benefits of solubilizing, and thus minimizing, intratubular precipitation of uric acid. The goal is to increase urinary pH to 7.0 to maximize uric acid solubility in renal tubules and vessels.
  • Drawbacks to systemic alkaline therapy include magnification of clinical hypocalcemia by shifting ionized calcium to its nonionized form. Increased likelihood of calcium phosphate precipitation in renal tubules is an additional drawback. For these reasons, routine urine alkalinization is controversial, and if it is employed it must include close monitoring of urinary pH, serum bicarbonate, and uric acid levels to both guide therapy and avoid overzealous alkalinization. Consider withdrawing sodium bicarbonate from intravenous fluid solutions once serum bicarbonate levels reach 30 mEq/L, urinary pH exceeds 7.5, or serum uric acid levels have normalized.
  • If urinary alkalinization is not achieved with exogenous bicarbonate solutions despite increasing serum bicarbonate levels, intravenous acetazolamide at doses of 250-500 mg/d (5 mg/kg/d) may be added to decrease proximal tubule bicarbonate reabsorption, thereby increasing urinary pH.
• Diuretics
• • Use of furosemide or mannitol for osmotic diuresis has not proven to be beneficial as front-line therapy. In fact, these modalities may contribute to uric acid or calcium phosphate precipitation in renal tubules in a volume-contracted patient.
  • Instead, diuretics should be reserved for well-hydrated patients with insufficient diuresis, and furosemide alone should be considered for the normovolemic patient with hyperkalemia or for the patient with evidence of fluid overload.
• Control of electrolyte disturbances
• • Aggressively treat and monitor hyperkalemia. Immediately restrict dietary potassium and remove potassium from intravenous fluids. Acute treatment modalities include intravenous infusion of glucose plus insulin to promote redistribution of potassium from the extracellular to intracellular space, and intravenous calcium gluconate as cardioprotection for potassium levels greater than 6.5 mmol/L or for those with ECG alterations. Intravenous hydration with alkaline fluid as already described also can increase intracellular uptake of potassium. Potassium-wasting diuretics may be employed with caution since these may worsen renal precipitation in the volume-contracted patient. Long-term therapy such as oral potassium-exchange resins should be given immediately because of the transient effectiveness of acute treatment modalities. If these measures fail to control serum potassium, dialysis should be initiated promptly.
  • Hyperphosphatemia is managed with oral phosphate binders and the same solution of glucose plus insulin used for control of hyperkalemia. Hyperphosphatemia may lead to hypocalcemia, which usually resolves as phosphate levels are corrected. In some cases, depressed serum 1,25-dihydroxycholecalciferol levels contribute to hypocalcemia, and administration of calcitriol may correct calcium levels. Such therapy, however, should not be undertaken until serum phosphate levels have normalized to avoid metastatic calcium phosphate calcifications. As a rule, do not correct hypocalcemia unless evidence of neuromuscular irritability exists, as indicated by a positive Chvostek or Trousseau sign.
• Dialysis
• • If the previously mentioned methods fail, consider early initiation of dialysis. Dialysis will avoid irreversible renal failure and other life-threatening complications. Indications for dialysis include persistent hyperkalemia or hyperphosphatemia despite treatment, volume overload, uremia, symptomatic hypocalcemia, and hyperuricemia.
  • Hemodialysis is preferred over peritoneal dialysis because of better phosphate and uric acid clearance rates. Continuous hemofiltration also has been used and is effective in correcting electrolyte abnormalities and fluid overload.
  • Because hyperkalemia can recur after dialysis is initiated and because of the high phosphate burden in some patients with tumor lysis syndrome, electrolyte levels must be monitored frequently and dialysis repeated as needed.

Consultations

• If initial supportive care measures fail to control electrolyte disturbances or renal failure, nephrology and critical care consultations are important for assistance in further management.
• Should dialysis become necessary, consultation with a surgeon to place an appropriate vascular access device is required.

MEDICATION

Section 7 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

The goals of pharmacotherapy are to reduce morbidity and to prevent complications.

Drug Category: Uricosurics

These agents control hyperuricemia and attempt to prevent urate nephropathy and subsequent oliguric renal failure.

Drug Name	Rasburicase (Elitek)
Description	A recombinant form (derived from Saccharomyces cerevisiae-synthesized, Aspergillus flavus) of the enzyme urate oxidase, which oxidizes uric acid to allantoin. Indicated for treatment and prophylaxis of severe hyperuricemia associated with the treatment of malignancy. Hyperuricemia causes a precipitant in the kidneys, which leads to ARF. Unlike uric acid, allantoin is soluble and easily excreted by the kidneys. Elimination half-life is 18 h.
Adult Dose	0.15-0.2 mg/kg/d IV infused over 30 min for 5 d; dilute in 50 mL 0.9% NaCl
Pediatric Dose	Administer as in adults
Contraindications	Documented hypersensitivity; G-6-PD deficiency; pregnancy
Interactions	None reported
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	May cause hemolytic anemia secondary to hydrogen peroxide produced during uric acid oxidation; may cause methemoglobinemia; other adverse effects include fever, nausea, or vomiting; children <2 y may experience more vomiting, diarrhea, fever, and rash; avoid shaking or vortexing during product reconstitution; highly antigenic, multiple administration may produce allergic reaction, anaphylaxis, or death; produces false low uric acid levels, accurate levels obtained by collecting blood into prechilled, heparin-containing tubes kept at 4°C and centrifuged at that temperature, maintain resultant plasma at 4°C and analyze within 4 h of collection

Drug Category: Alkalinizing agents

These agents may prevent the crystallization of uric acid.

Drug Name	Sodium bicarbonate (Neut)
Description	Used IV to alkalinize urine. Promotes alkaline diuresis with potential benefits of solubilizing, and thus minimizing, intratubular precipitation of uric acid. Goal is to increase urinary pH to 7 to maximize uric acid solubility in renal tubules and vessels. Routine urine alkalinization is controversial, and if employed must include close monitoring of urinary pH, serum bicarbonate, and uric acid levels. Consider withdrawing sodium bicarbonate from IVF solutions once serum bicarbonate levels reach 30 mEq/L, urinary pH >7.5, or serum uric acid levels have normalized.
Adult Dose	1 ampule (44 mEq) of sodium bicarbonate is added to 1 L of 0.45% isotonic saline and infused at 100 cc/h IV
Pediatric Dose	1.9 mEq/kg IV q1-2h prn
Contraindications	Documented hypersensitivity; alkalosis; hypernatremia; hypocalcemia; severe pulmonary edema; abdominal pain of unknown cause
Interactions	Urinary alkalinization, induced by increased sodium bicarbonate concentrations, may decrease levels of lithium, tetracyclines, chlorpropamide, methotrexate, and salicylates; increases levels of amphetamines, pseudoephedrine, flecainide, anorexiants, mecamylamine, ephedrine, quinidine, and quinine
Pregnancy	C - Safety for use during pregnancy has not been established.
Precautions	Can cause alkalosis, decreased plasma potassium, hypocalcemia and hypernatremia; caution in electrolyte imbalances (eg, patients with CHF, cirrhosis, edema, corticosteroid use, renal failure); when administering, avoid extravasation since can cause tissue necrosis

Drug Category: Electrolytes

These agents are used to prevent and treat hyperkalemia and restore electrolyte balance.

Drug Name	Calcium gluconate (Kalcinate)
Description	Used for cardioprotection for potassium levels >6.5 mmol/L or for patients with ECG alterations. Moderates nerve and muscle performance, and facilitates normal cardiac function.
Adult Dose	100-300 mg elemental calcium IV diluted in 150 mL D5W over 10 min; initial rate of infusion should be 0.3-2 mg of elemental calcium/kg/h
Pediatric Dose	2 mg/kg of elemental calcium IV (about 20 mg/kg of calcium gluconate 10%)
Contraindications	Documented hypersensitivity; renal calculi; hypercalcemia; hypophosphatemia; renal or cardiac disease; digitalis toxicity
Interactions	May decrease effects of tetracyclines, atenolol, salicylates, iron salts, and fluoroquinolones; antagonizes effects of verapamil; large intakes of dietary fiber may decrease absorption and levels
Pregnancy	B - Usually safe but benefits must outweigh the risks.
Precautions	Caution in digitalized patients, respiratory failure, acidosis, or severe hyperphosphatemia

Drug Category: Diuretics

These agents should be reserved for well-hydrated patients with insufficient diuresis.

FOLLOW-UP

Section 8 of 9  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

Further Inpatient Care

• Please refer to Medical Care.

In/Out Patient Meds

• Please refer to Medical Care.

Deterrence/Prevention

• Patients without laboratory evidence of TLS who remain at high risk should have prophylactic measures begun 24-48 hours prior to initiation of cytotoxic therapy. Prophylactic measures include liberal intravenous fluid administration, allopurinol, and urinary alkalinization. Close monitoring of fluid status and blood chemistry is important and should continue until 48-72 hours after chemotherapy initiation. Please refer to the previous section on Medical Care for more information.

Complications

• Potential complications include uremia and oliguric renal failure due to tubule precipitation of uric acid, calcium phosphate, or hypoxanthine.
• Severe electrolyte disturbances, such as hyperkalemia and hypocalcemia, predispose patients to cardiac arrhythmia.
• Iatrogenic complications, such as pulmonary edema from overly vigorous hydration or metabolic alkalosis from excess exogenous administration of bicarbonate, also can occur and are life threatening if not immediately addressed.

REFERENCES

Section 9 of 9

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• References

• Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol. May 1993;13(3):273-80. [Medline].
• Arrowsmith ER, Greer JP, Macon WR. Complications of hematopoietic neoplasms. In: Wintrobe's Clinical Hematology. 1999:2052-5.
• Bishop MR, Coccia PF. Tumor lysis syndrome. In: Abeloff, ed. Clinical Oncology. 2000:750-3.
• Browning LA, Kruse JA. Hemolysis and methemoglobinemia secondary to rasburicase administration. Ann Pharmacother. 2005;39(11):1932-5.
• Chen SW, Hwang WS, Tsao CJ, Liu HS, Huang GC. Hydroxyurea and splenic irradiation-induced tumour lysis syndrome: a case report and review of theliterature. J Clin Pharm Ther. 2005;30(6):623-625.
• Cohen LF, Balow JE, Magrath IT, et al. Acute tumor lysis syndrome. A review of 37 patients with Burkitt''s lymphoma. Am J Med. Apr 1980;68(4):486-91. [Medline].
• Del Toro G, Morris E, Cairo MS. Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches. Review. Clin Adv Hematol Oncol. Jan 2005;3(1):54-61.
• Ezzone SA. Tumor lysis syndrome. Semin Oncol Nurs. Aug 1999;15(3):202-8. [Medline].
• Fleming DR, Doukas MA. Acute tumor lysis syndrome in hematologic malignancies. Leuk Lymphoma. Nov 1992;8(4-5):315-8. [Medline].
• Flombaum CD. Metabolic emergencies in the cancer patient. Semin Oncol. Jun 2000;27(3):322-34. [Medline].
• Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin''s lymphoma. Am J Med. Feb 1993;94(2):133-9. [Medline].
• Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy. Dec 2005;25(12):1820-5.
• Jones DP, Mahmoud H, Chesney RW. Tumor lysis syndrome: pathogenesis and management. Pediatr Nephrol. Apr 1995;9(2):206-12. [Medline].
• Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med. Nov 1997;103(5):363-7. [Medline].
• Kelly KM, Lange B. Oncologic emergencies. Pediatr Clin North Am. Aug 1997;44(4):809-30. [Medline].
• Klinenberg JR, Kippen I, Bluestone R. Hyperuricemic nephropathy: pathologic features and factors influencing urate deposition. Nephron. 1975;14(1):88-98. [Medline].
• Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I. Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Med Oncol. 2005;22(2):203-6.
• Lazarus JM, Brenner BM. Chronic renal failure. In: Harrison's Principles of Internal Medicine. 1998:1513-20.
• Lee CC, Wu YH, Chung SH, Chen WJ. Acute tumor lysis syndrome after thalidomide therapy in advanced hepatocellular carcinoma. Oncologist. 2006;11(1):87-88.
• Lorigan PC, Woodings PL, Morgenstern GR, Scarffe JH. Tumour lysis syndrome, case report and review of the literature. Ann Oncol. Aug 1996;7(6):631-6. [Medline].
• Mahmoud HH, Leverger G, Patte C, et al. Advances in the management of malignancy-associated hyperuricaemia. Br J Cancer. Jun 1998;77 Suppl 4:18-20. [Medline].
• Obrador GT, Price B, O''Meara Y, Salant DJ. Acute renal failure due to lymphomatous infiltration of the kidneys. J Am Soc Nephrol. Aug 1997;8(8):1348-54. [Medline].
• Rohaly-Davis J, Johnston K. Hematologic emergencies in the intensive care unit. Crit Care Nurs Q. Feb 1996;18(4):35-43. [Medline].
• Yim BT, Sims-McCallum RP, Chong PH. Rasburicase for the treatment and prevention of hyperuricemia. Ann Pharmacother. Jul-Aug 2003;37(7-8):1047-54. [Medline].

Article Last Updated: Dec 18, 2006